IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,091 shares of the company's stock after selling 1,966 shares during the period. Public Employees Retirement System of Ohio's holdings in IDEXX Laboratories were worth $17,729,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. International Assets Investment Management LLC grew its stake in IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Clearbridge Investments LLC increased its stake in shares of IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock valued at $171,891,000 after buying an additional 308,493 shares during the period. Vontobel Holding Ltd. raised its holdings in shares of IDEXX Laboratories by 3,325.0% in the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company's stock valued at $111,229,000 after acquiring an additional 213,731 shares in the last quarter. American Century Companies Inc. lifted its stake in IDEXX Laboratories by 46.0% in the second quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock worth $274,179,000 after acquiring an additional 177,226 shares during the period. Finally, 1832 Asset Management L.P. grew its holdings in IDEXX Laboratories by 4,193.1% during the 2nd quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company's stock worth $62,601,000 after acquiring an additional 125,498 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research reports. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Piper Sandler reaffirmed a "neutral" rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Barclays reduced their price target on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $539.63.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares of the company's stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Stock Down 1.7 %

Shares of IDXX traded down $7.64 during mid-day trading on Wednesday, hitting $437.08. 566,714 shares of the company traded hands, compared to its average volume of 513,294. The company has a market capitalization of $35.79 billion, a PE ratio of 42.19, a price-to-earnings-growth ratio of 3.98 and a beta of 1.37. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average of $442.37 and a 200 day moving average of $472.89. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. IDEXX Laboratories's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.53 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.